Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1693
Full metadata record
DC FieldValueLanguage
dc.contributorDagan, M.en_US
dc.contributorDinh, D.en_US
dc.contributorStehli, J.en_US
dc.contributorTan, C.en_US
dc.contributorBrennan, A.en_US
dc.contributorAjani, A.en_US
dc.contributorOqueli, Ernestoen_US
dc.contributorKaye, D.en_US
dc.contributorFreeman, M.en_US
dc.contributorReid, C.en_US
dc.contributorHiew, C.en_US
dc.contributorClark, D.en_US
dc.contributorDuffy, S.en_US
dc.date.accessioned2021-01-06T22:40:52Z-
dc.date.available2021-01-06T22:40:52Z-
dc.date.issued2020-
dc.identifier.govdoc01642en_US
dc.identifier.urihttp://hdl.handle.net/11054/1693-
dc.description.abstractBackground: Left ventricular dysfunction and ischaemic heart disease (IHD) are common amongst women, however, women tend to present later and are less likely to receive guideline-directed medical therapy compared to men. Methods: We analysed prospectively collected data (2005-2018) from a multicentre registry on optimal medical therapy (OMT) 30-days post-percutaneous coronary intervention in 13,015 patients with left ventricular ejection fraction <50%. OMT was defined as beta-blocker (BB), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB)±mineralocorticoid receptor antagonist (MRA). Long-term mortality was determined by linkage with the National Death Index. Results: Mean age was 65±12 years; women represented 20% (2,634) of the cohort. Women were on average 5-years older, with higher BMI, higher rates of hypertension, diabetes, renal dysfunction, prior stroke and rheumatoid arthritis. OMT was similar between sexes (72.7% vs 72.2%, p=0.58). BB therapy was also similar between sexes (85.2% vs 84.5%, p=0.38), while women were less likely to be on an ACEi/ARB (80.4% vs 82.4%, p=0.02) and more likely to be on a MRA (12.1% vs 10.0%, p=0.003). Women were less likely to be on statin therapy (p<0.001) or a second antiplatelet agent (p=0.007). Women had higher unadjusted long-term mortality (25% vs 19%, p<0.001), though not on multivariable analysis (HR 0.99, 95% CI 0.87-1.14, p=0.94). Conclusion: Rates of OMT for left ventricular dysfunction were similar between sexes, however women were less likely to be on appropriate IHD secondary prevention. The increased unadjusted long-term mortality amongst women is likely due to differing baseline risk, given that adjusted mortality was similar between sexes.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2021-01-05T23:46:02Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2021-01-06T22:40:52Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2021-01-06T22:40:52Z (GMT). No. of bitstreams: 0 Previous issue date: 2020en
dc.titleSex differences in pharmacotherapy and long-term outcomes in patients with ischaemic heart disease and left ventricular dysfunction.en_US
dc.typeConferenceen_US
dc.type.specifiedPaperen_US
dc.bibliographicCitation.conferencedateDecember 11-13en_US
dc.bibliographicCitation.conferencename68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meetingen_US
dc.bibliographicCitation.conferenceplaceOnlineen_US
dc.subject.healththesaurusCARDIOVASCULAR DISEASEen_US
dc.subject.healththesaurusWOMENS HEALTHen_US
dc.subject.healththesaurusSEX DISCREPANCYen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.